Lung cancer vaccine trial continues at UKs Markey Cancer Center
Two University of Kentucky researchers continue their work with a vaccine to prevent lung cancer recurrences in patients following primary treatment of the disease.
Vaccines are being developed with the hope of reducing the unacceptably high rates of recurrence and disease progression seen in the treated lung cancer population. The cancer vaccine program is now enrolling a second cohort of subjects to study the effects of the vaccine in lung cancer patients. The vaccine is delivered following conventional treatment with surgery, radiation therapy or chemotherapy and the patients evaluated for immune responses that could indicate clinical benefit.
Edward A. Hirschowitz, M.D., Associate professor of medicine, and John Yannelli, Ph.D., Associate professor of Microbiology and Immunology, both in the UK College of Medicine, are using white blood cells from the patients blood to make the vaccine. They then administer the vaccine to the patient which allows the patients immune system to recognize and destroy tumor cells that can lead to recurrences after cancer treatment.
"This trial is important in the fight against lung cancer because additional medical therapies are not generally recommended until recurrences are seen," said Hirschowitz. "We are using the window between definitive medical or surgical therapy and lung cancer recurrence to enhance the immune response to a cancer recurrence."
The vaccine in this study uses dendritic cells, the most potent immune inducing cells found in the human body. In the lab these cells can be grown in large numbers then programmed with tumor information that directs the immune system to recognize and kill tumor cells in the body.
"UK is in the forefront of cancer research and therapy with this study," said Yannelli. "Only in the past five years have scientists learned to grow these cells in large numbers and manipulate their biology in laboratory culture. As a result, we can experimentally culture these cells in the lab and inject patients with more of these potent cells to engineer immune responses to different diseases."
In the previous cohort the researchers had very positive biological results and patient outcomes. In this second group, the researchers hope to treat 30 new patients over a period of two years. Each patient receives two injections of the dendritic cells, one month apart. It takes seven days to make the vaccine. Following careful monitoring to insure the vaccine is safe, the antigen loaded dendritic cells are injected into the patient. The second dose is administered a month later.
Initially, the Kentucky Lung Cancer Tobacco Settlement Foundation gave the researchers $200,000 to start the project and an additional; $500,000 was secured from the Cancer Treatment Research Foundation. They have recently secured another grant for $700,000 to further their efforts.
Kentucky has the highest incidence of lung cancer in the country. "Kentucky has such a devastating problem, developing vaccines research here is really important. A seemingly endless stream of lung cancer patients seen in our clinics continually reinforces the importance of this research. " said Hirschowitz "UK is one of the prevailing lung cancer vaccine centers in the U.S."
Louise DuPont | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...